1. Home
  2. FRPT vs RARE Comparison

FRPT vs RARE Comparison

Compare FRPT & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Freshpet Inc.

FRPT

Freshpet Inc.

N/A

Current Price

$57.72

Market Cap

2.7B

ML Signal

N/A

Logo Ultragenyx Pharmaceutical Inc.

RARE

Ultragenyx Pharmaceutical Inc.

N/A

Current Price

$14.75

Market Cap

2.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FRPT
RARE
Founded
2004
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.6B
IPO Year
2014
2013

Fundamental Metrics

Financial Performance
Metric
FRPT
RARE
Price
$57.72
$14.75
Analyst Decision
Buy
Buy
Analyst Count
17
20
Target Price
★ $84.25
$28.05
AVG Volume (30 Days)
878.4K
★ 5.9M
Earning Date
11-02-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 183.87
7.31
EPS
★ 1.29
N/A
Revenue
★ $1,102,015,000.00
$673,000,000.00
Revenue This Year
$11.17
$13.37
Revenue Next Year
$8.54
$31.21
P/E Ratio
$44.19
★ N/A
Revenue Growth
13.01
★ 20.13
52 Week Low
$46.45
$12.73
52 Week High
$86.00
$39.89

Technical Indicators

Market Signals
Indicator
FRPT
RARE
Relative Strength Index (RSI) 25.23 37.44
Support Level $51.41 $13.81
Resistance Level $58.16 $16.12
Average True Range (ATR) 1.81 0.82
MACD -0.50 0.50
Stochastic Oscillator 13.62 73.45

Price Performance

Historical Comparison
FRPT
RARE

About FRPT Freshpet Inc.

Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. Freshpet primarily targets dogs (likely representing well north of 90% of sales), with cats and treats nascent contributors. Geographically, the company's home US market, where all its food is produced, accounts for nearly all of sales, with exports to Canada, the United Kingdom, and other European countries being very small contributors.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Share on Social Networks: